Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region
- PMID:32718965
- PMCID: PMC7508590
- DOI: 10.1128/AAC.00797-20
Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region
Abstract
Emerging carbapenem resistance inEscherichia coli, including sequence type 131 (ST131), the leading cause of extraintestinalE. coli infections globally, threatens therapeutic efficacy. Accordingly, we determined broth microdilution MICs for three distinctive newer agents, i.e., cefiderocol (CFDC), ceftazidime-avibactam (CZA), and eravacycline (ERV), plus 11 comparators, against 343 carbapenem-resistant (CR) clinicalE. coli isolates, then compared susceptibility results with bacterial characteristics and region. The collection comprised 203 U.S. isolates (2002 to 2017) and 141 isolates from 17 countries in Europe, Latin America, and the Asia-West Pacific region (2003 to 2017). Isolates were characterized for phylogenetic group, resistance-associated sequence types (STs) and subsets thereof, and relevant beta-lactamase-encoding genes. CFDC, CZA, and ERV exhibited the highest percent susceptible (82% to 98%) after tigecycline (TGC) (99%); avibactam improved CZA's activity over that of CAZ (11% susceptible). Percent susceptible varied by phylogroup and ST for CFDC and CZA (greatest in phylogroups B2, D, and F, and in ST131, ST405, and ST648). Susceptibility also varied by resistance genotype, being higher with theKlebsiella pneumoniae carbapenemase (KPC) for CZA, lower with metallo-beta-lactamases for CFDC and CZA, and higher with the beta-lactamase CTX-M for ERV. Percent susceptible also varied by global region for CZA (lower in Asia-Pacific) and by U.S. region for ERV (lower in the South and Southeast). Although resistance to comparators often predicted reduced susceptibility to a primary agent (especially CFDC and CZA), even among comparator-resistant isolates the primary-agent-susceptible fraction usually exceeded 50%. These findings clarify the likely utility of CFDC, CZA, and ERV against CRE. coli in relation to multiple bacterial characteristics and geographical region.
Keywords: E. coli; KPC; MIC; ST131-H30; carbapenem resistant; cefiderocol; ceftazidime-avibactam; coresistance; eravacycline; metallo-beta-lactamase.
Similar articles
- Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-20017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and coresistance.Johnston BD, Thuras P, Porter SB, Clabots C, Johnsona JR.Johnston BD, et al.Diagn Microbiol Infect Dis. 2021 May;100(1):115314. doi: 10.1016/j.diagmicrobio.2021.115314. Epub 2021 Jan 21.Diagn Microbiol Infect Dis. 2021.PMID:33578059
- Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.Johnston BD, Thuras P, Porter SB, Anacker M, VonBank B, Vagnone PS, Witwer M, Castanheira M, Johnson JR.Johnston BD, et al.Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02408-19. doi: 10.1128/AAC.02408-19. Print 2020 Apr 21.Antimicrob Agents Chemother. 2020.PMID:32152073Free PMC article.
- In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.Bianco G, Boattini M, Comini S, Iannaccone M, Bondi A, Cavallo R, Costa C.Bianco G, et al.Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):63-70. doi: 10.1007/s10096-021-04341-z. Epub 2021 Aug 31.Eur J Clin Microbiol Infect Dis. 2022.PMID:34462816
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.Zhanel GG, et al.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.Drugs. 2019.PMID:30712199Review.
- Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI.Karakonstantis S, et al.Clin Microbiol Infect. 2024 Feb;30(2):178-188. doi: 10.1016/j.cmi.2023.08.029. Epub 2023 Sep 4.Clin Microbiol Infect. 2024.PMID:37666449Review.
Cited by
- Treatment of Severe Infections Due to Metallo-BetalactamasesEnterobacterales in Critically Ill Patients.Timsit JF, Wicky PH, de Montmollin E.Timsit JF, et al.Antibiotics (Basel). 2022 Jan 24;11(2):144. doi: 10.3390/antibiotics11020144.Antibiotics (Basel). 2022.PMID:35203747Free PMC article.Review.
- Clinical Distribution Characteristics of 1439 Carbapenem-ResistantEscherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90.Zhang W, Li Z, Wang N, Yang Z, Li J, Li C, Han X, Liu J, Li L, Wang S, Zhan M.Zhang W, et al.Infect Drug Resist. 2021 Nov 12;14:4717-4725. doi: 10.2147/IDR.S334283. eCollection 2021.Infect Drug Resist. 2021.PMID:34795488Free PMC article.
- Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.Syed YY.Syed YY.Drugs. 2021 Sep;81(13):1559-1571. doi: 10.1007/s40265-021-01580-4. Epub 2021 Aug 24.Drugs. 2021.PMID:34427896Free PMC article.Review.
- Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.Larcher R, Laffont-Lozes P, Roger C, Doncesco R, Groul-Viaud C, Martin A, Loubet P, Lavigne JP, Pantel A, Sotto A.Larcher R, et al.Front Cell Infect Microbiol. 2022 Dec 5;12:1048633. doi: 10.3389/fcimb.2022.1048633. eCollection 2022.Front Cell Infect Microbiol. 2022.PMID:36544909Free PMC article.
- Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ.Tamma PD, et al.Clin Infect Dis. 2022 Aug 25;75(2):187-212. doi: 10.1093/cid/ciac268.Clin Infect Dis. 2022.PMID:35439291Free PMC article.
References
- Livorsi DJ, Chorazy ML, Schweizer MS, Balkenende EC, Blevins AE, Nair R, Samore MH, Nelson RE, Khader K, Perencevich EN. 2018. A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States. Antimicrob Resist Infect Control 7:55. doi:10.1186/s13756-018-0346-9. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical